The novel family of Warbicin® compounds inhibits glucose uptake both in yeast and human cells and restrains cancer cell proliferation.
Saved in:
| Title: | The novel family of Warbicin® compounds inhibits glucose uptake both in yeast and human cells and restrains cancer cell proliferation. |
|---|---|
| Authors: | Vanthienen W; Center for Microbiology, VIB, Leuven-Heverlee, Belgium.; Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven-Heverlee, Belgium., Fernández-García J; VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium., Baietti MF; TRACE PDX Platform, Laboratory of RNA Cancer Biology, LKI Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Claeys E; TRACE PDX Platform, Laboratory of RNA Cancer Biology, LKI Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Van Leemputte F; Center for Microbiology, VIB, Leuven-Heverlee, Belgium.; Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven-Heverlee, Belgium., Nguyen L; Screening Core, VIB, Ghent, Belgium.; Centre for Bioassay Development and Screening (C-BIOS), Ghent University, Ghent, Belgium., Goossens V; Screening Core, VIB, Ghent, Belgium.; Centre for Bioassay Development and Screening (C-BIOS), Ghent University, Ghent, Belgium., Deparis Q; Center for Microbiology, VIB, Leuven-Heverlee, Belgium.; Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven-Heverlee, Belgium., Broekaert D; VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium., Vlayen S; LKI Leuven Cancer Institute Leuven, KU Leuven, Leuven, Belgium., Audenaert D; Screening Core, VIB, Ghent, Belgium.; Centre for Bioassay Development and Screening (C-BIOS), Ghent University, Ghent, Belgium., Delforge M; LKI Leuven Cancer Institute Leuven, KU Leuven, Leuven, Belgium., D'Amuri A; Anatomic Pathology Unit, 'A. Perrino' Hospital, Brindisi, Italy., Van Zeebroeck G; Center for Microbiology, VIB, Leuven-Heverlee, Belgium.; Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven-Heverlee, Belgium., Leucci E; TRACE PDX Platform, Laboratory of RNA Cancer Biology, LKI Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Fendt SM; VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium., Thevelein JM; Center for Microbiology, VIB, Leuven-Heverlee, Belgium.; Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven-Heverlee, Belgium.; NovelYeast bv, Bio-Incubator, BIO4, Leuven-Heverlee, Belgium. |
| Source: | Frontiers in oncology [Front Oncol] 2024 Aug 22; Vol. 14, pp. 1411983. Date of Electronic Publication: 2024 Aug 22 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
